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ABSTRACT:  Terminalia belerica (behada) fruit has been evaluated as a promising agent 
against E. histolytica and a variety of bacteria associated with dysentery and diarrhoea.  These 
in vitro studies were extended further for evaluating clinical efficacy among patients of acute 
and chronic cases of diarrhoea and dysentery.  The Studies were carried out on 25 patients by 
five medical practitioners practicing at different clinics in the urban areas of Pune.  The data 
was collected as per the protocol given to the concerned clinicians.  Inclusion and exclusion 
criteria were critically followed.  Record of patients’ history, clinical evaluations and 
investigations like stool, urine examination were carried out where necessary. 
 
The maximum treatment period was 14 days and the dose was 150 mg. tablets of bioactive 
fraction three times a day.  11 out of 12 patients responded to therapy and required around 
twelve tablets for recovery.  Seven patients having the presence of cyst of amoeba, E. coli etc. 
became negative at the end of treatment.  Improvement started on second day.  No side effects of 
any nature were observed. 
 
INTRODUCTION 
 
Terminalia belerica,  commonly known as 
Behada, Baheda and Bibhitaka is in wide 
use against variety of ailments.  It is one of 
the three myrobalans of the popular 
Ayurvedic drug Triphala.  Its use in 
dysentery and diarrhoea is indicated 
(Nadkarni, 1975).  In the extensive 
screening programme on Indian Medicinal 
Plants carried out at Central Drug Research 
Institute, Lucknow; number of plants were 
reported to be active against growth of E. 
histolytica (Dhar et al. 1973). 
 
From the thick seed coats of T. belerica 
fruits, ellagic, gallic and protocatechenic 
acids have been isolated from the 
polyphenolic fraction of lower 
chromatographic and electrophoretic 
mobilities by fractional precipitation.   
Besides these phenolic acids, free sugars 
have also been separated. (Row and Murthy 
1970), (Row, et al). 
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These studies were extended further by 
researchers at Regional Research 
Laboratory, Jammu Tawi, with primary aim 
to screen a limited number of readily 
available plants with antidysenteric 
reputation against axenic and polyaxenic 
cultures of E. histolytica and other bacterial 
species encountered in diarrhoea and 
dysentery.  In this program thirty five plants 
were  examined out of which the most 
significant activity was observed in 
Terminalia belerica. 
 
T. belerica fruit extract showed amoebicidal 
and bactericidal activity in vitro.  Its 
bactericidal activity was better than that of 
nalidixic acid and chloramphenicol (Bhutani 
et al., 1987). 
 
MATERIALS AND METHODS 
 
Bioactive fraction (BAF) was prepared by 
extraditing dry pericarp (3 Kg.) of the fresh 
fruits (20 Kg.) with hot methanol.  The 
methanol extract (300 g.) was vacuum dried 
is hot desicator till all the traces of solvent 
were evaporated.  Ayurvedic physicians 
recommend about 8 –  10 g. of Tirphala 
powder | day | patient for long term therapy 
without any adverse effects.  With this view 
of dose of BAF was designed. 
 
BAF prepared by the Regional Research 
Laboratory, Jammu Tawi, was formulated 
into tablets of 150mg. A common protocol 
was provided along with the drug to the 
clinicians.  25 patients were included in this 
preliminary study and were divided equally 
among five different clinicians.  The studies 
were carried out by them independently at 
their individual clinics.  Samples were coded 
and patients received either drug or placebo 
in random fashion.  The inclusion and 
exclusion criteria were also determined 
along with records of patient history.   
Patients were examined clinically and 
pathological investigations were 
recommended for confirmation if necessary. 
 
Dose recommended was 2 tablets TDS up to 
14 days.  The clinicians were allowed to 
stop the treatment in case of adverse 
reaction or complete recovery even before 
this time limit.  The clinicians were free to 
vary the dose from 1 TDS to 2 TDS 
depending on the severity of the disease as 
reflected by number of loose motions, 
duration of gripping and cramps. 
 
The results obtained from clinicians in form 
of the filled up protocol were analysed 
critically. 
 
RESULTS 
 
Twenty five patients suffering from 
diarrhoea were entered into the trial.  Their 
characteristics on entry are given in Table 1.  
They were given BAF | placebo tablets three 
times a day.  No other drug was 
administered.  However oral rehydration 
therapy was allowed in patients with mild to 
moderate degree of dehydration.  Total six 
patients required oral rehydration therapy.   
Three patients dropped out due to personal 
reasons.  The response to therapy in  all 
patients is given in the Table 2.  All patients 
responded to therapy with BAF tablets.   
Around twelve tablets were required for 
their recovery.  Cyst positive, bacteria 
positive patients from drug treatment group 
became negative.  However placebo group 
stools showed presence of the same even 
after seventh day. 
 
 
DISCUSSION 
 
Amoebic dysentery though labeled as 
tropical has incidences to the extent of 10% 
in the temperate zones also.  This disease 
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tropical countries.  Drugs available for 
treatment include, metronidazole, 
Quiniodochlor, diloxanide furoate, emetine 
etc. but most of these drugs have their own 
limitations and toxic effects giving rise to 
problems in patients compliance (Goodman 
and Gilman 1975). 
 
In the present study a possibility of new 
drug development against E. histolytica and 
bacteria involved in dysentery or diarrhoea 
has been explored.  The significance of this 
work is that most of the patients were 
relieved from the disease and became 
symptom-free within 2 – 3 days.  The drug 
did not show any side effects nor was there 
any problem of patient’s compliance. 
 
TABLE 1 
 
Patient characterstics on entry into the study (Mean ± SD) 
 
  BAF  Placebo 
No. of patients (End of Study) 
 
Median age 
 
Male | Female Ratio 
 
Median number of watery stools in the previous 24 hrs 
 
Median duration since watery stools (hrs) 
 
No. of patients with cysts 
 
12 
 
23.6 ± 2.5 
 
10 : 2 
 
8 ± 1.6 
 
22 
 
7 
10 
 
21.7±3.5 
 
8:2 
 
7 ± 1.6 
 
20 
 
6 
 
The extract chemistry of the active fraction 
has to be carried out in order to get an idea 
about the active ingredients.  The 
mechanism of activity of this preparation 
cannot be commented from this study.  It is 
possible that the amoebicidal and 
bactericidal effect of BAF is responsible for 
patients’ improvement.  In order to confirm 
this hypothesis a detailed chemical and 
biological screening programme has to be 
undertaken under multidisciplinary 
approach.  It is needless to stress the 
importance of such agents which can control 
effectively the pathogens which can develop 
or have developed resistance to current 
drugs. 
 
TABLE 2 
Response to therapy 
 
  BAF  Placebo 
No. of patients completed therapy 
 
No. of patients responded therapy by 48 hours 
 
No. of tables taken (Mean ± SD) 
12 
 
11* 
 
12 ± 2.8* 
10 
 
2 
 
42 ± 6.8 Pages  94 - 97 
 
Time from first & last dose (hrs.) 
 
Time from first dose to diarrhoea stopped (hrs) 
 
Time from first dose to cramps stopped (hrs.) 
 
 
42 ± 6.4* 
 
29.6 ± 2.8* 
 
38.4 ± 6.2* 
 
82 ± 6.2 
 
78 ± 8.6 
 
70 ± 8.2 
 
* Significantly different from control p < 0.05 
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